Galectin Therapeutics (GALT) EBITDA (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly EBITDA came in at -$4.1 million in Q1 2026, up 48.37% year-on-year from -$2.7 million in Q1 2025, and down 21.16% quarter-over-quarter from -$3.4 million in Q4 2025.
Galectin Therapeutics (GALT) EBITDA (2010 - 2026) Analysis & Trends
Galectin Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- On a quarterly basis, EBITDA rose 48.37% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was -$16.3 million, a 60.02% increase from a year earlier, with the FY2025 full-year figure at -$20.1 million, up 52.67% from the prior year.
- EBITDA fell to -$4.1 million in Q1 2026 per GALT's latest filing, from -$3.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$3.4 million in Q4 2025 and bottomed at -$12.4 million in Q4 2024.
- The 5-year median for EBITDA is -$9.2 million (2023), against an average of -$8.4 million.
- Across the five-year window, EBITDA tumbled 57.27% in 2022 and jumped 72.92% in 2025, its largest moves.
- Year by year, EBITDA stood at -$10.6 million in 2022, then increased by 10.08% to -$9.6 million in 2023, then declined by 29.99% to -$12.4 million in 2024, then soared by 72.92% to -$3.4 million in 2025, then dropped by 21.16% to -$4.1 million in 2026.
- Per Business Quant, the three latest GALT EBITDA figures stand at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.2 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | -4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.08 Mn |
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | -4.20 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | -7.90 Mn |
| Dec 31, 2024 | -12.43 Mn |
| Sep 30, 2024 | -9.07 Mn |
| Jun 30, 2024 | -11.29 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -9.17 Mn |
| Jun 30, 2023 | -9.00 Mn |
| Mar 31, 2023 | -10.34 Mn |
| Dec 31, 2022 | -10.63 Mn |
| Sep 30, 2022 | -8.12 Mn |
| Jun 30, 2022 | -9.66 Mn |
| Mar 31, 2022 | -9.94 Mn |
| Dec 31, 2021 | -7.43 Mn |
| Sep 30, 2021 | -8.24 Mn |
| Jun 30, 2021 | -8.19 Mn |